Kindred Biosciences, Inc. (NASDAQ: KIN) 31.2% LOWER; announced that it has re-assessed its atopic dermatitis program and the atopic dermatitis market and has decided to discontinue its AtoKin study in favor of directing resources toward other programs in its portfolio.
Array Biopharma (NASDAQ: ARRY) 21.7% HIGHER; announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. (NYSE: NVS) to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement is conditional on the closing of transactions announced by Novartis